BridgeMD
Tests treatment safety and results for Parkinson Disease
Official title This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
ClinicalTrials.gov ID: NCT07102342
What this study is testing
What is Human Dopaminergic Progenitor Cells?
Human Dopaminergic Progenitor Cells is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for parkinson disease.
Also referred to as NouvNeu001.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 75
You may be able to join if
- Male or female patient must be 30 to 75 years of age inclusive, at the time of signing the informed consent form (ICF). Type of Patient and Disease...
- Diagnosis of PD between past 4 to 20 years (meet MDS 2015 clinical diagnostic criteria for PD).
- H-Y staging (Appendix III) for "OFF" episodes is 2.5-4.0.
- MDS-UPDRS-III score \> 35, and positive for the Acute levodopa challenge test (ALCT) (improvement \> 30% for MDS UPDRS-III staging from OFF episodes...
- No significant change in UPDRS-III scores between the two visits during the screening period.
You likely can't join if
- Medical Conditions
- Atypical Parkinsonism (Parkinsonism-Plus syndrome, secondary parkinsonism, familial parkinsonism) Prior/Concomitant Therapy
- Patients who have had previous pallidotomy, DBS surgery, striatal or extrapyramidal surgery, brain stereotaxy, prior surgical or radiation therapy to...
- Patients who have a previous head CT/MRI examination showing cerebral trauma, vascular malformation, hydrocephalus, brain tumor, etc., and patients...
- Patients who have had previous cellular therapy.
- Patients who have used glucocorticoids for an extended period (≥14 days) and at high doses (equivalent to prednisone ≥ 20 mg/day or other...
See the full eligibility criteria
Who can join
- Male or female patient must be 30 to 75 years of age inclusive, at the time of signing the informed consent form (ICF). Type of Patient and Disease Characteristics
- Diagnosis of PD between past 4 to 20 years (meet MDS 2015 clinical diagnostic criteria for PD).
- H-Y staging (Appendix III) for "OFF" episodes is 2.5-4.0.
- MDS-UPDRS-III score \> 35, and positive for the Acute levodopa challenge test (ALCT) (improvement \> 30% for MDS UPDRS-III staging from OFF episodes to ON episodes) over two screening period visits. Baseline scores will...
- No significant change in UPDRS-III scores between the two visits during the screening period.
- Patients who take stable doing of dopamine drug for at least 4 weeks prior to receiving the study drug.
- No significant change in dose and dosing schedule of the prescribed medicines for PD during the screening period.
- Medically suitable for neurosurgery under general anesthesia.
- Acceptable laboratory test values during screening and prior to transplantation (Day 0):
- Absolute neutrophil count ≥ 2.0 × 109/L
- White blood cell count ≥ 4.0 × 109/L
- Platelet count ≥ 100 × 109/L
- Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN)
- Total bilirubin ≤ 1.5 x ULN
- Serum creatinine ≤ 1.5 x ULN
- eGFR ≥ 50 mL/min/1.73 m2
- Agree to postpone any additional neurosurgical procedures, including DBS, until completion of the 12-month follow-up study (unless recommended by a neurologist).
- Agree not to participate in any other therapeutic intervention study within 24 months after neurosurgery.
- Able to participate in all study visits and evaluations, including brain/spine MRI, CT and PET scan. Weight Body mass index (BMI) within the range of 18\~32 kg/m2 (inclusive) with a minimum body weight of 45 kg at...
- Contraceptive use by men and women for 12 months after neurosurgery should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Informed Consent
- Able to understand the rationale of the clinical trial and sign the ICF. Other Agree not to receive COVID-19 vaccine within 14 days before neurosurgery, and not to receive any other vaccine within 30 days after...
What rules you out
- Medical Conditions
- Atypical Parkinsonism (Parkinsonism-Plus syndrome, secondary parkinsonism, familial parkinsonism) Prior/Concomitant Therapy
- Patients who have had previous pallidotomy, DBS surgery, striatal or extrapyramidal surgery, brain stereotaxy, prior surgical or radiation therapy to the brain or spinal cord, or other brain surgery; as well as other...
- Patients who have a previous head CT/MRI examination showing cerebral trauma, vascular malformation, hydrocephalus, brain tumor, etc., and patients who have brain imaging abnormalities in the striatum or other brain...
- Patients who have had previous cellular therapy.
- Patients who have used glucocorticoids for an extended period (≥14 days) and at high doses (equivalent to prednisone ≥ 20 mg/day or other glucocorticoids at equivalent doses) within 3 months prior to signing the ICF...
- Patients who have used immunosuppressive drugs for an extended period (≥14 days) within 3 months prior to signing the ICF.
- Patients who have used antipsychotics, such as antidepressants, antimanic drugs, etc. within 3 months prior to signing the ICF and are deemed by the investigator to potentially impact the study assessment.
- Patients who have used botulinum toxin or other drugs for dystonia or muscle spasticity within 6 months prior to signing the ICF and are deemed by the investigator to potentially impact the study assessment...
- Patients who are participating in other clinical trials, or have been enrolled in other clinical studies within 3 months prior to the screening
- Patients with poor compliance based on clinical evaluation of the investigator. Diagnostic Assessments
- Patients with a history of dementia or a severe cognitive disorder; or those with obvious dementia or congnitive impairment detected during screening; MDS-UPDRS congnitive impairment score (section 1.1) \> 3 point at...
- Severe depression as defined by HAMD ≥ 24 at screening.
- Severe anxiety as defined by HAMA ≥ 29 at screening.
- Patients with a history of psychiatric disorders that, in the investigator's opinion, make them unsuitable for participation; or patients with a history of suicidal ideation or suicide attempts within the past year or...
- Patients with abnormal coagulation (prothrombin time ≥ 1.5 ULN, activated partial thromboplastin time ≥ 1.5 ULN), or abnormal INR at screening.
- Patients cannot temporarily suspend anti-platelet agents or other anti-coagulant medications at least 5 days prior to investigational drug administration surgery.
- Patients with active disseminated intravascular coagulation and significant hemorrhagic tendency within 3 months prior to signing the ICF.
- Patients with current or history of following disease
- severe heart failure (congestive heart failure of New York Heart Association Class II or above), unstable angina pectoris, and myocardial infarction
- severe arrhythmia, including but not limited to second- or third-degree atrioventricular block, or prolonged QT interval.
- Long QT Syndrome.
- cardiovascular surgery (cardiac, vascular stent surgery, angioplasty).
- stroke or transient ischemic attack within 3 months prior to signing the ICF, as determined by the investigator to be unsuitable to participate the study.
- subarachnoid hemorrhage
- primary mitochondrial disorder, multiple sclerosis, or other neurodegenerative diseases such as Alzheimer's disease
- major vascular diseases (aortic aneurysm, aortic dissecting aneurysm, internal carotid artery stenosis), as determined by the investigator to be unsuitable to participate the study.
- previous or current malignant tumors
- immune disfunction, including autoimmune disease or immunocompromised state
- traumatic brain injury with loss of consciousness and residue neurologic symptoms
- active epilepsy or currently on anti-epileptic drugs
- Hypertensive patients with poorly controlled blood pressure (defined as blood pressure above 160/100 mmHg despite antihypertensive drugs treatment) and patients with severe postural hypotension
- Diabetic patients with poorly controlled blood glucose (glycosylated hemoglobin \> 9.0%, or fasting plasma glucose (FPG) ≥ 11.1mmol/L)
- Patients with clinically significant abnormalities in kidney or liver function at screening.
- Patient with clinically significant abnormalities in immunological tests at screening
- Patients with surgical contraindications (such as those with cochlear implant, cardiac pacemaker, cardiac defibrillator, stereotactic nucleus pallidotomy; Patients who have had unilateral or bilateral intraparenchymal...
- Patients with other combined severe systemic diseases, such as pulmonary heart disease, moderate to severe asthma, severe chronic obstructive pulmonary disease (COPD) (FEV1% \< 50%)
- Patients with serious infections, requiring antibiotic treatment within 2 weeks prior to signing the ICF
- Patients with any active infectious disease, including but not limited to positive for human immunodeficiency virus, SARS Covid-19 virus, syphilis antibody, quantitative HCV-RNA testing, quantitative HBV-DNA testing...
- Patients with alcohol or drug addiction
- Patients with contraindications or a history of allergy to any medicines used during the neurosurgical procedure.
- Patients with contraindication or a history of allergy to any medicines used during the study, such as immunosuppressants, levodopa, etc, or any of their components; Patients who are allergic to similar drugs or other...
- Female of childbearing potential who are not surgically sterilized/premenopausal/unwilling to use medically approved effective contraception during the study and lactating women; men who are not surgically...
- Patients who have received electric shock therapy within 30 days prior to the investigational drug administration surgery
- Patients who are participating in other clinical trials, or have been enrolled in other clinical studies within 3 months prior to the screening
- Patients with poor compliance based on clinical evaluation of the investigator
- Patients who are being treated with drugs such as neuroleptics, apomorphine, or levodopa/carbidopa infusion therapy
- Patients with severe dyskinesia in both "ON" and "OFF" drug states
- Patients who have received or will receive a live vaccine within 4 weeks prior to the study
- Patients with significant medical conditions, or with other conditions that, in the opinion of the investigator, are unsuitable to participate in the study
The study team makes the final eligibility decision.
Where it's taking place
- New York, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New York, New York, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.